ICD-10 Coding for P-Tau217 Testing in Alzheimer's Disease Evaluation
When ordering p-tau217 testing to evaluate for Alzheimer's disease, use the ICD-10 code that reflects the patient's current clinical presentation: G31.84 (Mild cognitive impairment) for MCI, G30.9 (Alzheimer's disease, unspecified) for suspected AD dementia, or R41.81 (Age-related cognitive decline) for subjective cognitive concerns with objective impairment.
Clinical Context for Appropriate Testing
Before ordering p-tau217, the patient must meet specific clinical criteria 1:
- Objective cognitive impairment documented on formal testing (not just subjective complaints)
- Clinical suspicion of AD based on comprehensive assessment
- Appropriate neuroimaging completed to rule out structural causes
- Collateral history supporting cognitive decline
Do not order p-tau217 for:
- Asymptomatic individuals (research only) 1
- Patients with subjective cognitive decline but normal objective testing 1
- Cases where non-neurodegenerative causes (anxiety, depression) are primary 1
- Rapidly progressive dementia where Creutzfeldt-Jakob disease is suspected (p-tau217 can be falsely elevated) 1
Specific ICD-10 Code Selection
For Mild Cognitive Impairment (MCI)
Use G31.84 when the patient has:
- Cognitive concern with objective impairment on testing
- Preserved independence in functional abilities
- Does not meet dementia criteria
- Clinical features suggesting possible AD etiology 2
For Suspected AD Dementia
Use G30.9 (or more specific G30.0 for early-onset, G30.1 for late-onset) when:
- Patient meets dementia criteria with significant functional impairment
- Clinical presentation consistent with AD
- Testing ordered to confirm AD pathology 2
For Subjective Cognitive Decline with Objective Findings
Use R41.81 when:
- Patient reports cognitive concerns
- Objective testing shows mild impairment below expected for age/education
- Does not yet meet MCI criteria but warrants biomarker evaluation 1
Important Caveats
P-tau217 is the preferred blood biomarker with superior diagnostic accuracy compared to p-tau181, p-tau231, or plasma Aβ42/Aβ40 ratio 1. However, results require careful interpretation:
- Two cut-point approach is mandatory: Results fall into low, indeterminate, or high ranges 1
- Approximately 20% of results will be indeterminate and require CSF or PET confirmation 1
- Confounding factors include renal failure (elevated eGFR affects levels), body mass index, and peripheral neuropathies 3, 4
- A high result must be interpreted with age and clinical context, as AD pathology increases with age even in cognitively normal individuals 1
Sample Handling Requirements
Ensure your laboratory follows proper protocols 1, 5:
- Non-adsorbent collection tubes
- Appropriate separation, cooling, and cold chain maintenance
- Testing in UKAS-accredited or equivalent clinical laboratory
- CE/CA marked assays (Lumipulse, ALZpath platforms validated) 5, 6
The ICD-10 code should reflect the clinical syndrome being evaluated, not the test being ordered. The p-tau217 test serves as an adjunct to comprehensive clinical assessment, never as a standalone diagnostic tool 1.